Interactions with Antiretroviral Drugs

ww w .h iv -d ru g in t er a c t ion s .org

Interactions with Antiretroviral Drugs Charts reviewed January 2017. Full information available at www.hiv-druginteractions.org

PIs

Atazanavir

Other

RAL

MVC

E/C/F/TDF

ZDV

DTG

TDF

d4T

3TC

FTC

FTC+TAF

ddI

ABC

RPV

RPV + FTC/TAF

NVP

EFV

DLV

OTHER

NRTIs

  F



 

Darunavir



O

 

Fosamprenavir

R

Indinavir



Lopinavir

P

Nelfinavir

E

Ritonavir

R

Saquinavir

S

Tipranavir

O

            

 N



Efavirenz

 A

Etravirine

 L

Nevirapine

 

Rilpivirine

 

Rilpivirine + FTC/TAF

   

Abacavir (ABC)

 U

Didanosine (ddI)

 S

Emtricitabine (FTC)

 E

Emtricitabine + TAF

  

Lamivudine (3TC)

 O 

Stavudine (d4T)

 N

Tenofovir-DF (TDF)

 L

Zidovudine (AZT/ZDV)

 Y

Dolutegravir

   

Elvitegravir/Cobi/F/TAF

   

Elvitegravir/Cobi/F/TDF

   

Enfuvirtide (T20)

 

Maraviroc

 

Raltegravir

 

For personal use only. Not for distribution.

  

Key to symbols

/

These drugs should not be coadministered

/

Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration

/

No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.

Co-formulations Combivir® Lamivudine + Zidovudine Kivexa® Abacavir + Lamivudine Trizivir® Abacavir + Lamivudine + Zidovudine Rezolsta®, Darunavir + Cobicistat Prezcobix® Triumeq® Abacavir + Lamivudine + Dolutegravir Truvada® Emtricitabine + Tenofovir-DF Descovy® Emtricitabine + Tenofovir alafenamide Atripla® Efavirenz + Emtricitabine + Tenofovir-DF Complera®, Eviplera® Rilpivirine + Emtricitabine + Tenofovir-DF Odefsey® Rilpivirine + Emtricitabine + Tenofovir alafenamide Genvoya® Elvitegravir + Cobicistat + Emtricitabine + Tenofovir alafenamide Stribild® Elvitegravir + Cobicistat + Emtricitabine + Tenofovir-DF





For personal use only. Not for distribution.

Filled symbols indicate further information on the interaction is available at www.hiv-druginteractions.org. Empty symbols indicate the combination has not been studied; an interaction has been predicted based on the metabolic profiles of the drugs.

Evotaz®

TPV

SQV

RTV

NFV

LPV

IDV

FPV

DRV

NNRTIs

Cobicistat

NNRTIs Delavirdine

NRTIs

Cobi

ATV

PROTEASE INHIBITORS

For personal use only. Not for distribution.

E/C/F/TAF

For personal use only. Not for distribution.

ETV

For personal use only. Not for distribution.

Page 1 of 1

   

  



For personal use only. Not for distribution.

Key to abbreviations ATV Cobi DRV FPV IDV LPV NFV

Atazanavir (Reyataz®) Cobicistat (Tybost®) Darunavir (Prezista®) Fosamprenavir (Telzir®, Lexiva®) Indinavir (Crixivan®) Lopinavir (Kaletra®) Nelfinavir (Viracept®)

RTV

Ritonavir (Norvir®)

SQV TPV

Saquinavir (Invirase®) Tipranavir (Aptivus®)

Atazanavir + Cobicistat

DTG E/C/F/TAF E/C/F/TDF MVC RAL

ABC ddI FTC 3TC d4T TDF ZDV

Abacavir (Ziagen®) Didanosine (Videx®, Videx-EC®) Emtricitabine (Emtriva®) Lamivudine (Epivir®) Stavudine (Zerit®) Tenofovir disoproxil fumarate (Viread®) Zidovudine (Retrovir®)

DLV EFV

Delavirdine (Rescriptor®) Efavirenz (Sustiva®, Stocrin®)

ETV NVP RPV

Etravirine (Intelence®) Nevirapine (Viramune®) Rilpivirine (Edurant®)

Dolutegravir (Tivicay®) Elvitegravir + Cobicistat + Emtricitabine + Tenofovir alafenamide Elvitegravir + Cobicistat + Emtricitabine+ Tenofovir disoproxil fumarate Maraviroc (Celsentri®, Selzentry®) Raltegravir (Isentress®)

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF. We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.